ERASCA INC (ERAS) Stock News
NASDAQ:ERAS - Nasdaq - US29479A1088 - Common Stock - Currency: USD
ERAS Latest News, Press Relases and Analysis
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
/PRNewswire/ -- USA News Group News Commentary – Immunotherapy is transforming oncology by harnessing the immune system's power to fight cancer like never...
Stellantis, PG&E And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized...
ERAS Stock Earnings: Erasca Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Erasca (NASDAQ:ERAS) just reported results for the second quarter of 2024.Erasc...
ERAS Stock Earnings: Erasca Misses EPS for Q2 2024
ERAS stock results show that Erasca missed analyst estimates for earnings per share the second quarter of 2024.
Erasca to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib plus trametinib reinforce therapeutic potential in NRASm melanoma and further support ongoing...
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing...
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding...
ERAS Stock Earnings: Erasca Misses EPS for Q1 2024
ERAS stock results show that Erasca missed analyst estimates for earnings per share the first quarter of 2024.
ERAS Stock Earnings: Erasca Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Erasca (NASDAQ:ERAS) just reported results for the fourth quarter of 2023.Erasc...
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors ...
Erasca Announces Pricing of Underwritten Offering of Common Stock
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
ERAS Stock Earnings: Erasca Beats EPS for Q4 2023
ERAS stock results show that Erasca beat analyst estimates for earnings per share the fourth quarter of 2023.
ERAS Stock Earnings: Erasca Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Erasca (NASDAQ:ERAS) just reported results for the first quarter of 2024.Erasca...
Erasca Reports First Quarter 2024 Business Updates and Financial Results
Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private...
Erasca Reports First Quarter 2024 Business Updates and Financial Results
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into H2 2026...
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into H2 2026
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts...
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
3 Penny Stocks You’ll Regret Not Buying Soon: December Edition
Consider the pros and cons of buying these penny stocks, which can deliver risk-adjusted returns to investors' portfolios.
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more...